Skip to content

Efficacy and safety of home-based light-emitting diodes in the treatment of sensitive skin syndrom

The mechanism and the efficacy and safety of home-based light-emitting diodes in the treatment of sensitive skin syndrom

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085011
Enrollment
Unknown
Registered
2024-05-29
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensitive skin syndrom

Interventions

Group A:Topical cream
Group B:Topical cream + LED Yellow light
Group C:Topical cream + LED Red-Yellow light

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for sensitive skin: (1) Subjective symptoms: Manifested as skin irritation by physical, chemical, mental and other factors, it is easy to burn, sting, itch and tightness; (2) Exclude primary diseases that may be accompanied by sensitive skin, such as: rosacea, seborrheic dermatitis, hormone-dependent dermatitis, contact dermatitis, atopic dermatitis and swollen lupus erythematosus; (2) Agree to conduct objective evaluation of the test (including lactate stinging test, capsaicin test and measurement of objective parameters); (3) Signed informed consent;

Exclusion criteria

Exclusion criteria: (1) Those who have oral contraceptives within half a year, pregnant or lactating women; (2) Patients with severe cardiovascular system diseases, severe liver and kidney insufficiency, elderly patients with a history of severe diabetes, and those with a history of mental illness; (3) Those who cannot avoid sun exposure due to long-term outdoor work; (4) Exclude primary diseases that may be accompanied by sensitive skin, such as: rosacea, seborrheic dermatitis, hormone-dependent dermatitis, contact dermatitis, atopic dermatitis and swollen lupus erythematosus; (5) Patients who have received oral medication (such as anti-inflammatory, antihistamines) and photoelectric therapy (such as intense pulsed light, radiofrequency) within two weeks before being included in the study; (6) Patients judged by the clinical trial investigator to be unsuitable for this trial; (7) Patients with a history of allergy to visible light or a positive photosensitivity test; (8) Patients who have recently participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
SS-10 score;

Secondary

MeasureTime frame
Erythema index, EI;transepidermal water loss, TEWL;pH;sebum content;

Countries

China

Contacts

Public ContactChengfeng Zhang

Huashan Hospital, Fudan University

e3dangdang@hotmail.com+86 138 1762 9772

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026